This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2011
  • /
  • 11
  • /
  • Jakafi (Incyte/Novartis) is FDA approved for Myelo...
Drug news

Jakafi (Incyte/Novartis) is FDA approved for Myelofibrosis

Read time: 1 mins
Last updated:16th Nov 2011
Published:16th Nov 2011
Source: Pharmawand
The FDA on 16 November 2011, approved Jakafi(ruxolitinib),from Incyte/Novartis, the first drug approved to specifically treat patients with the bone marrow disease Myelofibrosis. Jakafi is an inhibitor of JAK 1 and 2 (Janus Associated Kinase) that are involved in regulating blood and immunological functioning. The decision was based on two pivotal trials called COMFORT-1 and COMFORT-2.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.